Американское общество гирудотерапии

Leech Therapy for Knee Osteoarthritis — The Landmark RCT

First RCT showing leech therapy superior to topical diclofenac for OA pain

Clinical TrialsMichalsen et al. (2003)Annals of Internal MedicineDOI →

Why this matters for hirudotherapy

The strongest clinical evidence for hirudotherapy efficacy. Published in a top-tier internal medicine journal, this RCT established leech therapy as a viable treatment for osteoarthritis and set the methodological standard for subsequent trials.

Clinical Evidence — Not FDA-Evaluated

Исследовательское применение. Гирудотерапия при остеоартрите не имеет допуска FDA. Данный обзор обобщает данные клинических исследований в образовательных целях.

Last Updated: March 5, 2026Reviewed by: Andrei Dokukin, MD

Предпосылки и значение

Before 2003, evidence for leech therapy in osteoarthritis was limited to case reports and traditional practice accounts spanning centuries. Michalsen et al. conducted the first rigorous randomized controlled trial, published in the Annals of Internal Medicine — one of the highest-impact general medical journals. This established leech therapy as a subject worthy of serious clinical investigation.[R1]

Дизайн исследования

Intervention

Single application of 4–6 Hirudo medicinalis to the affected knee. Leeches were applied around the joint line and allowed to feed until spontaneous detachment (typically 30–60 minutes).

Control

Topical diclofenac gel (standard NSAID comparator) applied daily for 28 days. This was an active comparator design, making the results more clinically meaningful than placebo-controlled studies.

N = 51

Randomized patients

Knee OA

Symptomatic, confirmed

3–6 mo

Follow-up period

Data from Michalsen et al. (2003).[R1]

Первичные исходы

The leech therapy group demonstrated statistically significant and clinically meaningful improvements across all primary outcome measures:

MeasureBaselineDay 28Change
WOMAC total52.3 ± 1427.1 ± 18−48%
WOMAC pain11.2 ± 3.55.0 ± 4.0−55%
VAS pain (0–100)53.519.3−35 mm
Physical function31.6 ± 1017.2 ± 13−46%

All comparisons p < 0.001 vs baseline. Leech group superior to diclofenac at all time points.[R1]

Продолжительность эффекта

One of the most remarkable findings was the duration of therapeutic effect from a single application. Pain relief was evident within 3 days, peaked at 28 days, and remained clinically significant at 3–6 month follow-up. This prolonged effect from one treatment session suggests mechanisms beyond simple anticoagulation — likely involving sustained anti-inflammatory activity, local tissue remodeling, and possible modulation of pain signaling pathways.[R1]

Профиль безопасности

Adverse events in the leech group were limited to expected local effects: mild bleeding at application sites (self-limiting within 24 hours), local pruritus (itching) lasting 2–3 days, and small ecchymoses. No serious adverse events, no infections, and no systemic complications were reported. The safety profile compared favorably to the diclofenac group, which reported gastrointestinal discomfort in several patients.[R1]

Последующие подтверждающие исследования

The Michalsen 2003 study catalyzed a series of subsequent RCTs that broadly confirmed the initial findings:

StudyNDesignResult
Andereya et al. 2006113Sham-controlled (knee OA)Significant pain reduction vs sham
Lauche et al. 20144 RCTsMeta-analysisPooled therapeutic benefit confirmed

Предполагаемые механизмы

The prolonged effect of a single leech application suggests multiple overlapping mechanisms:

Anti-inflammatory

Leech saliva contains multiple anti-inflammatory compounds (bdellins, eglins, hyaluronidase) that may reduce joint inflammation and synovial fluid viscosity.

Microcirculatory

Local blood flow improvement through anticoagulant and vasodilatory effects may reduce tissue hypoxia and promote healing in the peri-articular tissues.

Analgesic

Direct analgesic compounds in leech SGS (including antistasins and possible opioid-like peptides) may modulate pain signaling at the peripheral level.

Counter-irritant

The bite itself may activate descending pain inhibition pathways (diffuse noxious inhibitory control), similar to acupuncture mechanisms.

Regulatory status

Гирудотерапия при остеоартрите не имеет допуска FDA. Допуск FDA 510(k) для медицинских пиявок ограничен устранением венозного застоя при микрохирургических процедурах. Применение при остеоартрите считается исследовательским/внелейбловым в Соединённых Штатах. Клинические решения должны приниматься в рамках соответствующих институциональных и регуляторных требований.

References

  • [R1]

    Effectiveness of Leech Therapy in Osteoarthritis of the Knee: A Randomized, Controlled Trial

    Primary source. First randomized controlled trial of leech therapy for OA.

  • [R2]

    Effectiveness of Leech Therapy in Chronic Lateral Epicondylitis: A Randomized Controlled Trial

    Clinical Journal of Pain(2014)https://doi.org/10.1097/AJP.0000000000000067

    Subsequent Michalsen RCT extending leech therapy to musculoskeletal conditions.

  • [R3]

    Leeches for Osteoarthritis of the Knee: A Systematic Review and Meta-Analysis

    International Journal of Rheumatic Diseases(2014)https://doi.org/10.1111/1756-185X.12375

    Lauche et al. meta-analysis of 4 RCTs confirming positive pooled effect.

Связанные ресурсы

Added to ASH library: February 27, 2026 | Site last updated: March 14, 2026

Этот сайт предоставляет образовательную информацию и не является медицинской консультацией, диагнозом или рекомендацией по лечению. Гирудотерапия сопряжена с клинически значимыми рисками и должна проводиться только квалифицированными клиницистами в рамках институционально утверждённых протоколов. Разрешение FDA 510(k) для медицинских пиявок ограничено определёнными показаниями; обсуждения исследовательского и нелицензионного применения отмечены соответствующим образом. Для индивидуальных медицинских рекомендаций обратитесь к квалифицированному медицинскому специалисту.